Saturday 17 October 2026
Export INGN’s income statement to Excel — free account
Inogen, Inc
INGN Healthcare Medical Devices
Inogen, Inc’s revenue for fiscal 2025 (year ended December 2025) was $348.7 million, up 3.86% from fiscal 2024. In the quarter to June 2026, revenue grew 3.04%, EPS grew 6.67% and free cash flow fell 51.2%, each against the same quarter a year earlier.
6.25
0.05
−0.79%
Follow INGN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.49 | 0.48 | 0.51 | 0.64 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
59.21 | (25.26) | (189.57) | 102.08 | |
P/B ratio |
1.00 | 0.92 | 0.93 | 1.12 | |
Price to Tangible BV |
1.27 | 1.18 | 1.19 | 1.43 | |
EV/Sales |
0.19 | 0.16 | 0.17 | 0.28 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(26.94) | (51.80) | (5.18) | (7.29) | |
EV/FCF |
(8.62) | (7.58) | (3.27) | (5.04) | |
Quick Ratio |
2.16 | 2.50 | 2.51 | 2.54 | |
Current Ratio |
2.74 | 3.10 | 3.12 | 3.14 | |
Net Debt/EBITDA |
267.77 | 25.15 | 28.30 | 65.63 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.19 | 1.18 | 1.17 | 1.13 | |
Operating CF/Net income |
(0.77) | 0.80 | 0.13 | (0.41) | |
Capex/Depreciation |
(0.35) | (0.04) | (0.19) | (0.30) | |
Research and Development Expense of Revenue |
6.17% | 5.99% | 6.51% | 5.24% | |
Selling, General and Administrative Expense of Revenue |
44.69% | 49.47% | 48.00% | 47.18% | |
Intangible Assets out of Total Assets |
0.13 | 0.14 | 0.14 | 0.14 | |
Share Based Compensation of Revenue |
1.86% | 2.29% | 2.22% | 1.91% | |
Graham Net Nets |
0.48 | 0.52 | 0.51 | 0.42 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(13.95%) | (14.72%) | (12.80%) | (12.36%) | |
Free Cash Flow Yield |
(4.50%) | (4.50%) | (9.95%) | (8.68%) | |
Revenue per Share |
3.52 | 3.12 | 3.07 | 3.41 | |
Operating CF per Share |
0.11 | (0.24) | (0.04) | 0.08 | |
Capex per Share |
(0.06) | (0.01) | (0.04) | (0.06) | |
Free Cash Flow per Share |
0.05 | (0.25) | (0.07) | 0.02 | |
Cash per Share |
3.95 | 4.08 | 4.54 | 4.60 | |
Shareholders Equity per Share |
6.47 | 6.69 | 7.23 | 7.28 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.47 | 6.69 | 7.23 | 7.28 | |
Free Cash Flow |
1.31 | (6.89) | (1.92) | 0.62 | |
Working Capital |
123.27 | 129.22 | 134.76 | 138.77 | |
Capital Expenditures |
(1.63) | (0.21) | (0.98) | (1.54) | |
Net Current Asset Value |
83.43 | 87.65 | 91.91 | 93.88 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.00 | 0.01 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
42.37 | 39.25 | 34.21 | 37.79 | |
Average Payables |
37.41 | 34.31 | 30.55 | 30.62 | |
Average Inventory |
26.47 | 25.63 | 25.39 | 24.20 | |
Average Assets |
298.81 | 297.17 | 297.41 | 306.59 | |
Average Common Equity |
187.18 | 190.43 | 183.05 | 191.29 |
Columns are period end dates